000124251 001__ 124251
000124251 005__ 20240228145502.0
000124251 0247_ $$2doi$$a10.1007/s12026-017-8904-4
000124251 0247_ $$2pmid$$apmid:28224362
000124251 0247_ $$2ISSN$$a0252-9564
000124251 0247_ $$2ISSN$$a0257-277X
000124251 0247_ $$2ISSN$$a0257-277x
000124251 0247_ $$2ISSN$$a1559-0755
000124251 0247_ $$2altmetric$$aaltmetric:19645744
000124251 037__ $$aDKFZ-2017-01147
000124251 041__ $$aeng
000124251 082__ $$a610
000124251 1001_ $$0P:(DE-HGF)0$$aSchmidt, Angelika$$b0$$eFirst author
000124251 245__ $$aAnalysis of FOXP3(+) regulatory T cell subpopulations in peripheral blood and tissue of patients with systemic lupus erythematosus.
000124251 260__ $$aTotowa, NJ$$bHumana Press$$c2017
000124251 3367_ $$2DRIVER$$aarticle
000124251 3367_ $$2DataCite$$aOutput Types/Journal article
000124251 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524660138_18387
000124251 3367_ $$2BibTeX$$aARTICLE
000124251 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000124251 3367_ $$00$$2EndNote$$aJournal Article
000124251 520__ $$aRegulatory T cells (Tregs) are critical mediators of immune tolerance, yet their involvement in the autoimmune disease systemic lupus erythematosus (SLE) is incompletely understood. We analyzed CD4(+) T cell subpopulations with Treg-related phenotypes and their association with disease activity in peripheral blood (PB) and tissues of patients with SLE. In detail, we quantified subpopulations regarding CD25, FOXP3, CD62L, CCR6, CD27, CD45RA, and CD45RO expression in PB from 31 patients with SLE divided into two disease activity groups and 32 healthy controls using flow cytometry. CD4(+) and FOXP3(+) T cells in skin and kidney biopsies of patients with SLE were quantified by immunohistochemistry. CD4(+)CD25(+/++)FOXP3(+) and CD4(+)CD25(+)CD45RA(-)/CD45RO(+) T cell frequencies were significantly higher in PB from patients with active compared to inactive SLE. The fraction of CD4(+)CD25(++)FOXP3(+) Tregs and CD4(+)CD25(+)CD45RA(+)/CD45RO(-) naïve Tregs was not significantly different between these groups. CD4(+)CD25(++) Tregs from active SLE patients comprised significantly less CD27(+) cells and more CCR6(+) cells compared to patients with inactive SLE. The percentage of CD4(+)FOXP3(+) T cells among inflammatory infiltrates in skin and kidney biopsies of SLE patients was not different from other inflammatory skin/kidney diseases. In conclusion, although CD4(+)FOXP3(+) T cell frequencies in the inflamed tissues of SLE patients were comparable to other inflammatory diseases, distinct T cell subpopulations appeared misbalanced in PB of patients with active SLE. Here, cells phenotypically resembling activated T cells, but not Tregs, were increased compared to patients with inactive SLE. Within Tregs of patients with active SLE, markers related to Treg function and homing were altered.
000124251 536__ $$0G:(DE-HGF)POF3-322$$a322 - Genetics and Pathophysiology (POF3-322)$$cPOF3-322$$fPOF III$$x0
000124251 588__ $$aDataset connected to CrossRef, PubMed,
000124251 7001_ $$0P:(DE-HGF)0$$aRieger, Cosima C$$b1
000124251 7001_ $$aVenigalla, Ram Kumar$$b2
000124251 7001_ $$aÉliás, Szabolcs$$b3
000124251 7001_ $$aMax, Regina$$b4
000124251 7001_ $$aLorenz, Hanns-Martin$$b5
000124251 7001_ $$0P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91$$aGröne, Hermann-Josef$$b6$$udkfz
000124251 7001_ $$0P:(DE-He78)92492c6eae05ee58973fc142c9201e3d$$aKrammer, Peter$$b7$$udkfz
000124251 7001_ $$0P:(DE-He78)c0c75f5b6bf92932ad4604214e94df78$$aKuhn, Annegret$$b8$$eLast author$$udkfz
000124251 773__ $$0PERI:(DE-600)2079303-0$$a10.1007/s12026-017-8904-4$$gVol. 65, no. 2, p. 551 - 563$$n2$$p551 - 563$$tImmunologic research$$v65$$x1559-0755$$y2017
000124251 909CO $$ooai:inrepo02.dkfz.de:124251$$pVDB
000124251 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000124251 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000124251 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000124251 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92492c6eae05ee58973fc142c9201e3d$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000124251 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c0c75f5b6bf92932ad4604214e94df78$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000124251 9131_ $$0G:(DE-HGF)POF3-322$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vGenetics and Pathophysiology$$x0
000124251 9141_ $$y2017
000124251 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000124251 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000124251 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bIMMUNOL RES : 2015
000124251 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000124251 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000124251 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000124251 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000124251 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000124251 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000124251 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000124251 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000124251 9201_ $$0I:(DE-He78)D030-20160331$$kD030$$lImmungenetik$$x0
000124251 9201_ $$0I:(DE-He78)G130-20160331$$kG130$$lZelluläre und Molekulare Pathologie$$x1
000124251 980__ $$ajournal
000124251 980__ $$aVDB
000124251 980__ $$aI:(DE-He78)D030-20160331
000124251 980__ $$aI:(DE-He78)G130-20160331
000124251 980__ $$aUNRESTRICTED